Physiological and pathological levels of prostaglandin E                         2                          in renal parenchyma and neoplastic renal tissue

Vittore Verratti; Luigi Brunetti; Claudio Ferrante; Giustino Orlando; Lucia Recinella; Annalisa Chiavaroli; Sheila Leone; Run Wang; Francesco Berardinelli

doi:10.1016/j.prostaglandins.2019.02.004

Physiological and pathological levels of prostaglandin E ₂ in renal parenchyma and neoplastic renal tissue

Vittore Verratti
, Luigi Brunetti
, Claudio Ferrante
, Giustino Orlando
, Lucia Recinella
, Annalisa Chiavaroli
, Sheila Leone
, Run Wang
, Francesco Berardinelli

McGovern Medical School at UTHealth Houston

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

Prostaglandin (PG)E ₂ seems to promote tumor proliferation by regulating cell growth, inhibiting apoptosis, promoting angiogenesis, and suppressing host immune surveillance of cancer cells. The suppression of prostaglandins biosynthesis is thought to be the main molecular mechanism for non-steroidal anti-inflammatory drugs antineoplastic effect. Yet the relationship between PGE ₂ and human renal cell carcinoma remains unclear. The aim of our study is to evaluate the PGE ₂ content in human renal parenchyma and Renal Cell Carcinoma. The study was conducted on 20 consecutive patients undergoing radical nephrectomy for Renal Cell Carcinoma. In the normal renal parenchyma and in the neoplastic renal tissue the PGE ₂ level was 83.43 ± 5.89 pg/mg and 289.67 ± 22.2 pg/mg, respectively (P < 0.0001). There was no relationship between PGE ₂ content and Renal Cell Carcinoma dimension, Fuhrman grade, pathological-Tumor-Node and Metastasis (pTNM) stage and histological subtype. The PGE ₂ over-content in neoplastic renal tissue suggests a role of PGE ₂ in development and progression of renal carcinoma.

Original language	English (US)
Pages (from-to)	11-13
Number of pages	3
Journal	Prostaglandins and Other Lipid Mediators
Volume	141
DOIs	https://doi.org/10.1016/j.prostaglandins.2019.02.004
State	Published - Apr 2019

Keywords

COX
PGE
Renal cell carcinoma
Renal parenchyma

ASJC Scopus subject areas

Biochemistry
Physiology
Pharmacology
Cell Biology

Access to Document

10.1016/j.prostaglandins.2019.02.004

Cite this

Verratti, V., Brunetti, L., Ferrante, C., Orlando, G., Recinella, L., Chiavaroli, A., Leone, S., Wang, R., & Berardinelli, F. (2019). Physiological and pathological levels of prostaglandin E ₂ in renal parenchyma and neoplastic renal tissue. Prostaglandins and Other Lipid Mediators, 141, 11-13. https://doi.org/10.1016/j.prostaglandins.2019.02.004

Verratti, V, Brunetti, L, Ferrante, C, Orlando, G, Recinella, L, Chiavaroli, A, Leone, S, Wang, R & Berardinelli, F 2019, 'Physiological and pathological levels of prostaglandin E ₂ in renal parenchyma and neoplastic renal tissue', Prostaglandins and Other Lipid Mediators, vol. 141, pp. 11-13. https://doi.org/10.1016/j.prostaglandins.2019.02.004

@article{17070f601b7f45a8a7c8c042285a3b9d,

title = "Physiological and pathological levels of prostaglandin E 2 in renal parenchyma and neoplastic renal tissue",

abstract = " Prostaglandin (PG)E 2 seems to promote tumor proliferation by regulating cell growth, inhibiting apoptosis, promoting angiogenesis, and suppressing host immune surveillance of cancer cells. The suppression of prostaglandins biosynthesis is thought to be the main molecular mechanism for non-steroidal anti-inflammatory drugs antineoplastic effect. Yet the relationship between PGE 2 and human renal cell carcinoma remains unclear. The aim of our study is to evaluate the PGE 2 content in human renal parenchyma and Renal Cell Carcinoma. The study was conducted on 20 consecutive patients undergoing radical nephrectomy for Renal Cell Carcinoma. In the normal renal parenchyma and in the neoplastic renal tissue the PGE 2 level was 83.43 ± 5.89 pg/mg and 289.67 ± 22.2 pg/mg, respectively (P < 0.0001). There was no relationship between PGE 2 content and Renal Cell Carcinoma dimension, Fuhrman grade, pathological-Tumor-Node and Metastasis (pTNM) stage and histological subtype. The PGE 2 over-content in neoplastic renal tissue suggests a role of PGE 2 in development and progression of renal carcinoma.",

keywords = "COX, PGE, Renal cell carcinoma, Renal parenchyma",

author = "Vittore Verratti and Luigi Brunetti and Claudio Ferrante and Giustino Orlando and Lucia Recinella and Annalisa Chiavaroli and Sheila Leone and Run Wang and Francesco Berardinelli",

note = "Publisher Copyright: {\textcopyright} 2019",

year = "2019",

month = apr,

doi = "10.1016/j.prostaglandins.2019.02.004",

language = "English (US)",

volume = "141",

pages = "11--13",

journal = "Prostaglandins and Other Lipid Mediators",

issn = "1098-8823",

publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Physiological and pathological levels of prostaglandin E 2 in renal parenchyma and neoplastic renal tissue

AU - Verratti, Vittore

AU - Brunetti, Luigi

AU - Ferrante, Claudio

AU - Orlando, Giustino

AU - Recinella, Lucia

AU - Chiavaroli, Annalisa

AU - Leone, Sheila

AU - Wang, Run

AU - Berardinelli, Francesco

PY - 2019/4

Y1 - 2019/4

N2 - Prostaglandin (PG)E 2 seems to promote tumor proliferation by regulating cell growth, inhibiting apoptosis, promoting angiogenesis, and suppressing host immune surveillance of cancer cells. The suppression of prostaglandins biosynthesis is thought to be the main molecular mechanism for non-steroidal anti-inflammatory drugs antineoplastic effect. Yet the relationship between PGE 2 and human renal cell carcinoma remains unclear. The aim of our study is to evaluate the PGE 2 content in human renal parenchyma and Renal Cell Carcinoma. The study was conducted on 20 consecutive patients undergoing radical nephrectomy for Renal Cell Carcinoma. In the normal renal parenchyma and in the neoplastic renal tissue the PGE 2 level was 83.43 ± 5.89 pg/mg and 289.67 ± 22.2 pg/mg, respectively (P < 0.0001). There was no relationship between PGE 2 content and Renal Cell Carcinoma dimension, Fuhrman grade, pathological-Tumor-Node and Metastasis (pTNM) stage and histological subtype. The PGE 2 over-content in neoplastic renal tissue suggests a role of PGE 2 in development and progression of renal carcinoma.

AB - Prostaglandin (PG)E 2 seems to promote tumor proliferation by regulating cell growth, inhibiting apoptosis, promoting angiogenesis, and suppressing host immune surveillance of cancer cells. The suppression of prostaglandins biosynthesis is thought to be the main molecular mechanism for non-steroidal anti-inflammatory drugs antineoplastic effect. Yet the relationship between PGE 2 and human renal cell carcinoma remains unclear. The aim of our study is to evaluate the PGE 2 content in human renal parenchyma and Renal Cell Carcinoma. The study was conducted on 20 consecutive patients undergoing radical nephrectomy for Renal Cell Carcinoma. In the normal renal parenchyma and in the neoplastic renal tissue the PGE 2 level was 83.43 ± 5.89 pg/mg and 289.67 ± 22.2 pg/mg, respectively (P < 0.0001). There was no relationship between PGE 2 content and Renal Cell Carcinoma dimension, Fuhrman grade, pathological-Tumor-Node and Metastasis (pTNM) stage and histological subtype. The PGE 2 over-content in neoplastic renal tissue suggests a role of PGE 2 in development and progression of renal carcinoma.

KW - COX

KW - PGE

KW - Renal cell carcinoma

KW - Renal parenchyma

UR - https://www.scopus.com/pages/publications/85061442456

UR - https://www.scopus.com/pages/publications/85061442456#tab=citedBy

U2 - 10.1016/j.prostaglandins.2019.02.004

DO - 10.1016/j.prostaglandins.2019.02.004

M3 - Article

C2 - 30742910

AN - SCOPUS:85061442456

SN - 1098-8823

VL - 141

SP - 11

EP - 13

JO - Prostaglandins and Other Lipid Mediators

JF - Prostaglandins and Other Lipid Mediators

ER -